IQVIA (IQV) Stock Price, News & Analysis

Company Overview

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

Key Stats

• Today's Range: $190.76 to $195.51
• 50-Day Range: $190.94 to $209.76
• 52-Week Range: $187.62 to $261.73
• Volume: 1.55 million shs
• Average Volume: 1.35 million shs
• Market Capitalization: $33.62 billion
• P/E Ratio: 25.46
• Dividend Yield: N/A
• Price Target: $251.22
• Consensus Rating: Moderate Buy

IQVIA Stock Analysis - MarketRank™

IQVIA scored higher than 99% of companies evaluated by MarketBeat, and ranked 14th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

IQVIA has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 17 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

IQVIA has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 12.34%

Earnings Growth

Earnings for IQVIA are expected to grow by 12.34% in the coming year, from $10.86 to $12.20 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IQVIA is 25.46, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.43.

Price to Earnings Ratio vs. Sector

The P/E ratio of IQVIA is 25.46, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 25.82.

Price to Earnings Growth Ratio

IQVIA has a PEG Ratio of 2.01. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

IQVIA has a P/B Ratio of 5.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.64% of the float of IQVIA has been sold short.

Short Interest Ratio / Days to Cover

IQVIA has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IQVIA has recently decreased by 3.62%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IQVIA does not currently pay a dividend.

Dividend Growth

IQVIA does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.69

Percentage of Shares Shorted

1.64% of the float of IQVIA has been sold short.

Short Interest Ratio / Days to Cover

IQVIA has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IQVIA has recently decreased by 3.62%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.93

News Sentiment

IQVIA has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 32 news articles for IQVIA this week, compared to 13 articles on an average week.

Search Interest

Only 4 people have searched for IQV on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 8 people have added IQVIA to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, IQVIA insiders have bought more of their company's stock than they have sold. Specifically, they have bought $255,740.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 1.60% of the stock of IQVIA is held by insiders.

Percentage Held by Institutions

89.62% of the stock of IQVIA is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IQV Stock Analysis - Frequently Asked Questions

How have IQV shares performed this year?

IQVIA's stock was trading at $196.51 at the start of the year. Since then, IQV stock has decreased by 2.8% and is now trading at $190.9350.
View the best growth stocks for 2025 here.

How were IQVIA's earnings last quarter?

IQVIA Holdings Inc. (NYSE:IQV) announced its quarterly earnings results on Thursday, February, 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by $0.21. IQVIA had a trailing twelve-month return on equity of 28.81% and a net margin of 8.91%.
Read the conference call transcript.

Does IQVIA have any subsidiaries?

The following companies are subsidiaries of IQVIA: Q2 Solutions, Linguamatics, Advanced Health Media LLC, DrugDev, Aileron Solutions, Novella Clinical LLC, 159 Solutions LLC, and more.

Who are IQVIA's major shareholders?

IQVIA's top institutional shareholders include Vanguard Group Inc. (11.09%), Canada Pension Plan Investment Board (2.36%), Geode Capital Management LLC (2.30%) and Alliancebernstein L.P. (1.98%). Insiders that own company stock include Ari Bousbib, Eric Sherbet, Constantinos Panagos, Kevin C Knightly and John G Danhakl.
View institutional ownership trends.

How do I buy shares of IQVIA?

Shares of IQV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of IQVIA own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IQVIA investors own include NVIDIA (NVDA), Chevron (CVX), Meta Platforms (META), Bristol-Myers Squibb (BMY), Advanced Micro Devices (AMD), Broadcom (AVGO) and McKesson (MCK).

Company Calendar

• Last Earnings: 2/06/2025
• Today: 2/22/2025
• Next Earnings (Estimated): 5/01/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Commercial physical research
• Sub-Industry: Business Services
• Current Symbol: NYSE:IQV
• CUSIP: N/A
• CIK: 1478242
• Web: www.iqvia.com
• Phone: (919) 998-2000
• Fax: N/A
• Employees: 88,000
• Year Founded: 2016

Price Target and Rating

• Average Stock Price Target: $251.22
• High Stock Price Target: $276.00
• Low Stock Price Target: $210.00
• Potential Upside/Downside: +31.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.90
• Research Coverage: 21 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $7.50
• Trailing P/E Ratio: 25.46
• Forward P/E Ratio: 17.58
• P/E Growth: 2.01
• Net Income: $1.37 billion
• Net Margins: 8.91%
• Pretax Margin: 10.83%
• Return on Equity: 28.81%
• Return on Assets: 7.02%

Debt

• Debt-to-Equity Ratio: 2.12
• Current Ratio: 0.84
• Quick Ratio: 0.84

Sales & Book Value

• Annual Sales: $15.41 billion
• Price / Sales: 2.18
• Cash Flow: $16.14 per share
• Price / Cash Flow: 11.83
• Book Value: $34.45 per share
• Price / Book: 5.54

Miscellaneous

• Outstanding Shares: 176,100,000
• Free Float: 173,282,000
• Market Cap: $33.62 billion
• Optionable: Optionable
• Beta: 1.48